Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytophage Technologies Ltd V.CYTO

Alternate Symbol(s):  CPTCF

Healthcare Biotechnology
Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals... see more

Recent & Breaking News (TSXV:CYTO)

VIDEO ENHANCED Cytophage Technologies Reports Positive Outcome from Innovative Bacteriophage Therapy in Patient with Antibiotic-Resistant Infection

TheNewsWire December 17, 2024

New Partnership Between Cytophage, Orthopedic Innovation Centre Targets Prosthetic Joint Infections Using Phage Therapy

TheNewsWire December 12, 2024

Cytophage Celebrates Opening of State-of-the-Art Phage Production Facility in Winnipeg

TheNewsWire December 5, 2024

Cytophage Reports Q3 2024 Financials and Business Update

TheNewsWire November 27, 2024

Cytophage Highlights Existing Phage Solutions to Recent Harmful Bacteria Outbreaks in Food Systems

TheNewsWire November 11, 2024

Cytophage CEO to Discuss Reshaping Healthcare Through Phage Therapies During 2024 Canada SynBio Conference

TheNewsWire October 4, 2024

Cytophage Reports Q2 Financials including Business Update for First Half of 2024

TheNewsWire August 28, 2024

Cytophage Launches Ready-to-Use Lyophilized Phage Tablets to Improve Gut Health in Poultry

TheNewsWire August 15, 2024

Cytophage Reports AGM Results and Announces Upcoming Investor Call

TheNewsWire June 27, 2024

Cytophage Expands Commercialization of Phage Products in Asian Poultry Market

TheNewsWire June 20, 2024

Cytophage CEO to Present at TEDx Winnipeg Event

TheNewsWire June 4, 2024

Cytophage Reports Q1 Financials and Provides Business Update

TheNewsWire May 30, 2024

Cytophage Strengthens Board of Directors

TheNewsWire May 27, 2024

Cytophage Announces Fiscal Year End 2023 Results

TheNewsWire April 30, 2024

Cytophage Appoints New Board Director

TheNewsWire April 16, 2024

Cytophage Provides Update on Bacteriophage Human Trial at The Ottawa Hospital

TheNewsWire April 2, 2024

Cytophage Provides Bacteriophages for Landmark Treatment of Joint Replacement Infection in Canada

TheNewsWire March 1, 2024

Cytophage Update on Upcoming Product for Egg Production in Canada

TheNewsWire February 12, 2024

Cytophage Technologies Ltd. Completes Reverse Takeover Transaction of Cuspis Capital III Ltd.

TheNewsWire February 2, 2024

Cuspis Capital III Ltd. Announces Filing of Filing Statement with Respect to its Qualifying Transaction

TheNewsWire February 2, 2024